research JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
Search
for
Sort by
Research
210-240 / 1000+ resultsresearch Vemurafenib-induced pityriasis amiantacea: a case report
Vemurafenib can cause scalp issues but can be managed without changing the dose.
research Doxazosin + finasteride in BPH with TPV ??? 25mL
research Tapinarof cream for atopic dermatitis: Pharmacokinetics, systemic exposure, and preliminary efficacy/safety results
Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
research Betapapillomaviruses in the anal canal of HIV positive and HIV negative men who have sex with men
HIV-positive men who have sex with men have a higher rate of anal beta-papillomavirus infections.
research An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa
Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.
research 264 CCR5 blockade shows prevention of alopecia areata development as well as improvement of alopecia areata
Blocking CCR5 can prevent and improve hair loss in alopecia areata.
research Demodex folliculitis
Demodex folliculitis can occur in HIV patients on HAART, and treatment may involve topical creams or medication changes.
research Valproic acid (Depakene). A new anticonvulsant agent
Valproic acid is an effective seizure medication with some temporary side effects.
research Systemic tofacitinib in paediatric alopecia areata
research A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
Avacopan may cause unexpected side effects, so early monitoring is important.
research PROTACs: A novel strategy for cancer drug discovery and development
PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
research Computational screening of repurposed drugs and natural products against SARS-Cov-2 main protease (Mpro) as potential COVID-19 therapies
Some existing drugs and natural products might work against COVID-19 by targeting the virus's main protease.
research Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
research Treatment of chronic type B hepatitis in Southeast Asia.
Interferon therapy is a promising and safe treatment for hepatitis B in Southeast Asia.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Factors Related to Hair Antiretroviral Concentration: A Systematic Review of Global Literature
Hair antiretroviral concentration is affected by hair type, segment position, housing, drug use, sexual behavior, kidney function, and genetics.
research 0955 Selective BET inhibition as potential hidradenitis suppurativa treatment
research Acyclovir Can Abort Rejection of Punch Grafts in Herpes-simplex-Induced Lip Leucoderma
Acyclovir can prevent rejection of skin grafts in herpes-related lip leucoderma.
research 575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies
INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
research A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive.
The combination of cyproterone acetate and testosterone enanthate is highly effective in preventing sperm production and could be a good reversible male contraceptive.
research Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
research Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
research SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
research Antiviral Drugs Screening for Swine Acute Diarrhea Syndrome Coronavirus
Five existing drugs may help fight Swine Acute Diarrhea Syndrome Coronavirus.
research 576 INTASYL PH-762: Intratumoral immunotherapy targeting PD-1
PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.